Device Technologies has announced the official inclusion of Route 92 Medical’s pioneering FreeClimb® system on the Australian Register of Therapeutic Goods (ARTG) (ARTG 515885, 516066 and 516067), making the innovative neurovascular intervention technology widely accessible across the country.

This marks the first availability of the FreeClimb® system outside of the USA, offering Australian clinicians access to cutting-edge procedural solutions previously available only via special access. The system helps clinicians work more confidently, removing the need for a microcatheter in every case and reducing the use of a guidewire in over 70% of procedures.

The Route 92 FreeClimb® system, with its atraumatic Tenzing delivery catheter, is the first technology of its kind available in the APAC region. It’s designed to make a real difference for neurovascular patients by changing the way procedures are performed.

Shaun Anderson, General Manager – Cardiovascular ANZ & Asia at Device Technologies, said: "Having FreeClimb included on the ARTG is a huge step forward for acute neurovascular care in Australia. This system streamlines the procedure and reduces time to reperfusion for clinicians, and ultimately, it’s about giving patients across Australia and New Zealand the best possible outcomes. We’re really excited to see it making a real difference here."

The ARTG-included FreeClimb® system will be distributed in Australia by Device Technologies, a leading provider of innovative medical solutions, ensuring hospitals and clinics across the country have rapid access to the technology.

Route 92 Medical is committed to improving outcomes for patients undergoing neurovascular interventions through innovative product design and a reimagined procedural approach. Founded by physicians in collaboration with leading clinicians worldwide, the company focuses on solving some of the biggest challenges in neurointervention to deliver meaningful solutions that enhance procedural and patient outcomes.